[mo_oauth_login]
Summary report
GENECODE AS
Date of report 16.05.2025
GENECODE AS
10362550 -
Registered
Founded in
15.01.1998
Fixed capital
75,600 €
Former names
- Balti Tehnoloogiaarenduse Osaühing
- Balti Tehnoloogiaarenduse AS
VAT
EE101059031
(start 12.06.2006)
| start | end |
|---|---|
| 12.06.2006 | - |
keywords
- geenitehnoloogia
- riik ja ühiskond
- teadusasutused
- teadustegevus tehnoloogias
GENECODE AS
Scores and ratings
Reputation score
3440
What is Reputation score?
Credit Score
Neutral
0.04
Credit score today
Neutral
0.04
2002
year
Open the reports you want to print
Employees and salaries
GENECODE AS
Number of employees and estimated average salaries?
| 2024 II | 2024 III | 2024 IV | 2025 I | |
| Number of employees | ...... | ...... | ...... | ...... |
| Average gross salary | ...... | ...... | ...... | ...... |
GENECODE AS
Employee taxes and performance analysis?
| Quarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
|---|---|---|---|---|
| 2025 I | ...... | ...... | ...... | ...... |
| 2024 IV | ...... | ...... | ...... | ...... |
| 2024 III | ...... | ...... | ...... | ...... |
| 2024 II | ...... | ...... | ...... | ...... |
| 2024 I | ...... | ...... | ...... | ...... |
| 2023 IV | ...... | ...... | ...... | ...... |
| 2023 III | ...... | ...... | ...... | ...... |
| 2023 II | ...... | ...... | ...... | ...... |
| 2023 I | ...... | ...... | ...... | ...... |
| 2022 IV | ...... | ...... | ...... | ...... |
| 2022 III | ...... | ...... | ...... | ...... |
| 2022 II | ...... | ...... | ...... | ...... |
| 2022 I | ...... | ...... | ...... | ...... |
| 2021 IV | ...... | ...... | ...... | ...... |
| 2021 III | ...... | ...... | ...... | ...... |
| 2021 II | ...... | ...... | ...... | ...... |
| 2021 I | ...... | ...... | ...... | ...... |
| 2020 IV | ...... | ...... | ...... | ...... |
| 2020 III | ...... | ...... | ...... | ...... |
| 2020 II | ...... | ...... | ...... | ...... |
| 2020 I | ...... | ...... | ...... | ...... |
| 2019 IV | ...... | ...... | ...... | ...... |
| 2019 III | ...... | ...... | ...... | ...... |
| 2019 II | ...... | ...... | ...... | ...... |
| 2019 I | ...... | ...... | ...... | ...... |
| 2018 IV | ...... | ...... | ...... | ...... |
| 2018 III | ...... | ...... | ...... | ...... |
| 2018 II | ...... | ...... | ...... | ...... |
| 2018 I | ...... | ...... | ...... | ...... |
| 2017 IV | ...... | ...... | ...... | ...... |
| 2017 III | ...... | ...... | ...... | ...... |
| 2017 II | ...... | ...... | ...... | ...... |
| 2017 I | ...... | ...... | ...... | ...... |
| 2016 IV | ...... | ...... | ...... | ...... |
| 2016 III | ...... | ...... | ...... | ...... |
| 2016 II | ...... | ...... | ...... | ...... |
| 2016 I | ...... | ...... | ...... | ...... |
| 2015 IV | ...... | ...... | ...... | ...... |
| 2015 III | ...... | ...... | ...... | ...... |
| 2015 II | ...... | ...... | ...... | ...... |
| 2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
GENECODE AS
Decision-makers?
Former decision-makers
Relations:
8
Turnover 2025:
3 462 128 €
Employees:
13
Paavo Pilv
★★★★
......
Credit Score: Borderline
Reputation score: 15230
Date of birth: ......
Active relations 8
171 followers
*
GENECODE AS
Former decision-makers?
Relations:
2
Turnover:
Employees:
MEHIS PILV
★★★★
......
Credit Score: Neutral
Reputation score: 1730
Date of birth: ......
Active relations 2
422 followers
Relations:
2
Turnover 2025:
2 703 338 €
Employees:
4
Kaupo Karelson
★★★★
......
Credit Score: Neutral
Reputation score: 2700
Date of birth: ......
Active relations 2
66 followers
Relations:
8
Turnover 2025:
3 462 128 €
Employees:
13
Paavo Pilv
★★★★
......
Credit Score: Borderline
Reputation score: 15230
Date of birth: ......
Active relations 8
171 followers
GENECODE AS
History of right of representation?
Field
Administrative Activities
Business age
27y
Beneficial country:
Estonia
1998
2002
2006
2010
2013
2017
2021
2025
1998
2000
2003
2005
2008
2010
2013
2015
2018
2020
2023
2025
GENECODE AS
Owners?
Former owners
Former owners
| Name | Credit Score | Payment | Beginning | Ending |
|---|---|---|---|---|
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... |
GENECODE AS
Other related parties?
Former other persons
Other related parties (invalid relations)
GENECODE AS
Subsidiaries and associates?
Former subsidiaries and associates
Former subsidiaries and associates
| Name | Credit Score | Payment | Beginning | Ending |
|---|---|---|---|---|
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... | ||
| ...... | ...... | ...... |
Beneficiaries
Volumes and values of beneficiaries' assets
Net asset value of the beneficiary
... €
Value of beneficiary companies using the income method
... €
Analytically identified company holdings and asset volumes
| Company name | Retained profits | Fixed assets | Balance sheet total | Holdings |
|---|---|---|---|---|
| ...... | ...... | ...... | ...... |
40%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
27%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
90%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
24.5%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
20%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
30%
|
| ...... | ...... | ...... | ...... |
80%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
30%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
59%
|
| ...... | ...... | ...... | ...... |
13%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
80%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
12.5%
|
| ...... | ...... | ...... | ...... |
30%
|
| ...... | ...... | ...... | ...... |
12.5%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
12.5%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
30%
|
| ...... | ...... | ...... | ...... |
72.5%
|
| ...... | ...... | ...... | ...... |
63.8%
|
| ...... | ...... | ...... | ...... |
40%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
50%
|
| ...... | ...... | ...... | ...... |
Net asset value of the beneficiary
... €
Value of beneficiary companies using the income method
... €
Analytically identified company holdings and asset volumes
| Company name | Retained profits | Fixed assets | Balance sheet total | Holdings |
|---|---|---|---|---|
| ...... | ...... | ...... | ...... |
26.8%
|
| ...... | ...... | ...... | ...... |
7%
|
| ...... | ...... | ...... | ...... |
9.4%
|
| ...... | ...... | ...... | ...... |
8.3%
|
| ...... | ...... | ...... | ...... |
32.5%
|
| ...... | ...... | ...... | ...... |
15%
|
| ...... | ...... | ...... | ...... |
10%
|
| ...... | ...... | ...... | ...... |
Net asset value of the beneficiary
... €
Value of beneficiary companies using the income method
... €
Analytically identified company holdings and asset volumes
| Company name | Retained profits | Fixed assets | Balance sheet total | Holdings |
|---|---|---|---|---|
| ...... | ...... | ...... | ...... |
7%
|
| ...... | ...... | ...... | ...... |
9.4%
|
| ...... | ...... | ...... | ...... |
8.3%
|
| ...... | ...... | ...... | ...... |
35%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
100%
|
| ...... | ...... | ...... | ...... |
40%
|
| ...... | ...... | ...... | ...... |
25%
|
| ...... | ...... | ...... | ...... |
Finances and assets
GENECODE AS
Goodwill| EUR | 2023 | 2024 | 2025 | Trend |
| Goodwill | ...... | ...... | ...... | |
| Goodwill | ...... | ...... | ...... |
GENECODE AS
Taxes paid and estimated average salaries| 2022 | 2023 | 2024 | 2025 | |
| National taxes | ...... | ...... | ...... | ...... |
| Labor taxes | ...... | ...... | ...... | ...... |
| Average gross salary | ...... | ...... | ...... | ...... |
GENECODE AS
Quarterly indicators| Quarter | Turnover | Taxed turnover | Labour productivity | Labour productivity | Employees | National taxes | Labor taxes |
|---|---|---|---|---|---|---|---|
| 2025 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2016 IV | ...... | ...... | ...... | ...... | ...... | ...... | ...... |
| 2016 III | ...... | ...... | ...... | ...... | ...... | ...... | ...... |
| 2016 II | ...... | ...... | ...... | ...... | ...... | ...... | ...... |
| 2016 I | ...... | ...... | ...... | ...... | ...... | ...... | ...... |
| 2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
| 2015 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
GENECODE AS
Sales revenue by business arearevenue
| Field of activity | EMTAK code | Sales revenue (2020) | Sales revenue % |
| Research activities in biotechnology | 72111 | 4250 € | 100,00 |
GENECODE AS
Sales revenue by country| Turnover EUR | 2023 | 2024 prognosis | 2025 prognosis | Trend |
| Total sales | ...... | ...... | ...... | |
| Estonia | ...... | ...... | ...... | |
| Total exports | ...... | ...... | ...... |
GENECODE AS
Financial indicators and prognosis| Financial indicators | 2023 | 2024 Prognosis | 2025 Prognosis |
Trend |
| TURNOVER | ...... | ...... | ...... | |
| Estonia | ...... | ...... | ...... | |
| Other countries | ...... | ...... | ...... | |
| INTEREST INCOME | ...... | ...... | ...... | |
| OTHER BUSINESS INCOME | ...... | ...... | ...... | |
| TURNOVER IN RELATED COMPANY | ...... | ...... | ...... | |
| BTD MEDIC OÜ - % | ...... | ...... | ...... | |
| NEURONCODE AS - % | ...... | ...... | ...... | |
| OLICODE AS - % | ...... | ...... | ...... | |
| CERE CODE AS - % | ...... | ...... | ...... | |
| AVERAGE MONTHLY TURNOVER | ...... | ...... | ...... | |
| Available credit (credit limit) | ...... | ...... | ...... | |
| Settlement dates | ...... | ...... | ...... | |
| RECEIVED GRANTS € | ...... | ...... | ...... | |
| Majandus- ja Kommunikatsiooniministeerium | ...... | ...... | ...... | |
| TENDERS WON € | ...... | ...... | ...... | |
| ASSETS | ...... | ...... | ...... | |
| Current assets | ...... | ...... | ...... | |
| Fixed assets | ...... | ...... | ...... | |
| LIABILITIES | ...... | ...... | ...... | |
| Short-term liabilities | ...... | ...... | ...... | |
| Long-term liabilities | ...... | ...... | ...... | |
| EQUITY | ...... | ...... | ...... | |
| Share-(equity capital) | ...... | ...... | ...... | |
| Retained profits | ...... | ...... | ...... | |
| Net profit | ...... | ...... | ...... | |
| NET WORKING CAPITAL | ...... | ...... | ...... | |
| NUMBER OF EMPLOYEES | ...... | ...... | ...... |
GENECODE AS
Financial raiting: "SATISFACTORY" (2025 prognosis)| Multipliers and income levels | 2024 prognosis | 2025 prognosis |
Trend |
| LIQUIDITY | ...... | ...... | |
| Net Working capital | ...... | ...... | |
| Short-term debt coverage ratio (X) | ...... | ...... | |
| EFFECTIVENESS | ...... | ...... | |
| Debt to assets ratio (X) | ...... | ...... | |
| Capitalisation multiplier (X) | ...... | ...... | |
| USE OF LOAN CAPITAL | ...... | ...... | |
| Turnover ratio of fixed assets (X) | ...... | ...... | |
| PROFITABILITY | ...... | ...... | |
| Sales revenues (%) | ...... | ...... | |
| Total asset revenues (%) | ...... | ...... | |
| Equity revenues (%) | ...... | ...... |
2025 prognosis
LIQUIDITY
?
Net Working capital
...
Short-term debt coverage ratio
...
USE OF LOAN CAPITAL
?
Turnover ratio of fixed assets (X)
...
EFFECTIVENESS
?
Debt to assets ratio (X)
...
Capitalisation multiplier (X)
...
PROFITABILITY
?
Sales revenues (%)
...
Total asset revenues (%)
...
Equity revenues (%)
...
Unsatisfactory
1
2
3
4
5
Very good
GENECODE AS
Annual reports| Year | Period | Submitted | Report PDF |
|---|---|---|---|
| 2023 | 01.01.2023–31.12.2023 | 05.04.2024 | ...... |
| 2022 | 01.01.2022–31.12.2022 | 20.06.2023 | ...... |
| 2021 | 01.01.2021–31.12.2021 | 06.06.2022 | ...... |
| 2020 | 01.01.2020–31.12.2020 | 03.09.2021 | ...... |
| 2019 | 01.01.2019–31.12.2019 | 10.11.2020 | ...... |
| 2018 | 01.01.2018–31.12.2018 | 23.04.2020 | ...... |
| 2017 | 01.01.2017–31.12.2017 | 17.10.2018 | ...... |
| 2016 | 01.01.2016–31.12.2016 | 23.10.2017 | ...... |
| 2015 | 01.01.2015–31.12.2015 | 23.05.2016 | ...... |
| 2014 | 01.01.2014–31.12.2014 | 02.07.2015 | ...... |
| 2013 | 01.01.2013–31.12.2013 | 20.11.2014 | ...... |
| 2012 | 01.01.2012–31.12.2012 | 12.09.2014 | ...... |
| 2011 | 01.01.2011–31.12.2011 | 02.10.2012 | ...... |
| 2010 | 01.01.2010–31.12.2010 | 07.06.2011 | ...... |
| 2009 | 01.01.2009–31.12.2009 | 27.05.2010 | ...... |
| 2008 | 01.01.2008–31.12.2008 | 02.07.2009 | ...... |
| 2007 | 01.01.2007–31.12.2007 | 18.06.2008 | ...... |
| 2006 | 01.01.2006–31.12.2006 | 18.06.2007 | ...... |
| 2005 | 01.01.2005–31.12.2005 | 09.06.2006 | ...... |
| 2004 | 01.01.2004–31.12.2004 | 30.06.2005 | ...... |
| 2003 | 01.01.2003–31.12.2003 | 21.06.2004 | ...... |
| 2002 | 01.01.2002–31.12.2002 | 19.06.2003 | ...... |
| 2001 | 01.01.2001–31.12.2001 | 16.10.2002 | ...... |
Liabilities and debts
GENECODE AS
Credit score history and prognosisRecommended credit limit
... €
Recommended payment term
......
Business risk classes:
Trustworthy Neutral
Borderline
Problematic
Risky
GENECODE AS
Reports and assets-liabilities overview 16.05.2025?
Annual reports:
......
Annual reports: ......
Tax declarations:......
Assets to cover liabilities (short-term)
Assets: ...... €1 EURO of assets to cover short-term debt obligations: ...... €
Liabilities: ...... €Net Working capital: ...... €
GENECODE AS
Claims history?
1 month
6 months
Year
5 years
MAX
1 month
6 months
Year
5 years
MAX
Debt claims as of ......
Total debt claims: ...... €
Latest events
| ...... | ...... |
GENECODE AS
Income (turnover) and expenditure (taxes paid)?
| Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
|---|---|---|---|---|---|
| 2025 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 IV | ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 III | ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 II | ...... € | ...... € | ...... € | ...... € | ...... |
| 2016 I | ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 II | * ...... € | ...... € | ...... € | ...... € | ...... |
| 2015 I | * ...... € | ...... € | ...... € | ...... € | ...... |
GENECODE AS
Bailiff's enforcement proceedings as of 16.05.2025?
Bailiff's enforcement proceedings MISSING
GENECODE AS
Regulations of the Payment Order Department as of 16.05.2025?
Regulations of the Payment Order Department MISSING
GENECODE AS
Court orders in the register as of 16.05.2025?
Puuduste kõrvaldamise määrus kandeväliste andmete parandamiseks
20.01.2025
Regulation number: Ä 10022922 / M9
Regulation status has entered into force: 20.01.2025
Date of enforcement of order or additional period: 20.01.2025
Regulation status: Jõustunud
Korraldav määrus
19.10.2020
Regulation number: Ä 10022922 / M8
Regulation status has entered into force: 19.10.2020
Date of enforcement of order or additional period: 19.10.2020
Regulation status: Jõustunud
Eitav kandemäärus: puudused kõrvaldamata
02.03.2020
Regulation number: Ä 10022922 / 14
Regulation status has entered into force: 16.03.2020
Date of enforcement of order or additional period: 18.03.2020
Regulation status: Jõustunud
Puuduste kõrvaldamise määrus
07.01.2020
Regulation number: Ä 10022922 / M7
Regulation status has entered into force: 07.01.2020
Date of enforcement of order or additional period: 07.01.2020
Regulation status: Jõustunud
GENECODE AS
Decisions of the Consumer Disputes Committee as of 16.05.2025?
Consumer disputes MISSING
GENECODE AS
Court hearings as of 16.05.2025?
Court hearings MISSING
GENECODE AS
Rulings as of 16.05.2025?
Court settlemets MISSING
GENECODE AS
Notices and announcements as of 16.05.2025?
Announcements MISSING
Marketing
Business network
GENECODE AS
Business networkCREDIT RISK CLASSES
Deleted
Trustworthy
Neutral
Borderline
Problematic
Risky
Historical connection
Active connection
amount of turnover
amount of debt
Extension of networks
The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
GENECODE AS
Networks - Beneficiaries
The network is visible with reduced links
Expand threads if desired
Sign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events found.
Failed to load monitoring events.